EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas
BackgroundDiffuse large B-cell lymphoma (DLBCL) is a hematological malignancy representing one-third of non-Hodgkin’s lymphoma cases. Notwithstanding immunotherapy in combination with chemotherapy (R-CHOP) is an effective therapeutic approach for DLBCL, a subset of patients encounters treatment resi...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1266265/full |
| _version_ | 1827762809614630912 |
|---|---|
| author | Alice Turdo Miriam Gaggianesi Caterina D’Accardo Gaetana Porcelli Sebastiano Di Bella Dario Cricchio Irene Pillitteri Rossana Porcasi Melania Lo Iacono Francesco Verona Chiara Modica Narges Roozafzay Ada Maria Florena Giorgio Stassi Salvatrice Mancuso Matilde Todaro Matilde Todaro |
| author_facet | Alice Turdo Miriam Gaggianesi Caterina D’Accardo Gaetana Porcelli Sebastiano Di Bella Dario Cricchio Irene Pillitteri Rossana Porcasi Melania Lo Iacono Francesco Verona Chiara Modica Narges Roozafzay Ada Maria Florena Giorgio Stassi Salvatrice Mancuso Matilde Todaro Matilde Todaro |
| author_sort | Alice Turdo |
| collection | DOAJ |
| description | BackgroundDiffuse large B-cell lymphoma (DLBCL) is a hematological malignancy representing one-third of non-Hodgkin’s lymphoma cases. Notwithstanding immunotherapy in combination with chemotherapy (R-CHOP) is an effective therapeutic approach for DLBCL, a subset of patients encounters treatment resistance, leading to low survival rates. Thus, there is an urgent need to identify predictive biomarkers for DLBCL including the elderly population, which represents the fastest-growing segment of the population in Western countries.MethodsGene expression profiles of n=414 DLBCL biopsies were retrieved from the public dataset GSE10846. Differentially expressed genes (DEGs) (fold change >1.4, p-value <0.05, n=387) have been clustered in responder and non-responder patient cohorts. An enrichment analysis has been performed on the top 30 up-regulated genes of responder and non-responder patients to identify the signatures involved in gene ontology (MSigDB). The more significantly up-regulated DEGs have been validated in our independent collection of formalin-fixed paraffin-embedded (FFPE) biopsy samples of elderly DLBCL patients, treated with R-CHOP as first-line therapy.ResultsFrom the analysis of two independent cohorts of DLBCL patients emerged a gene signature able to predict the response to R-CHOP therapy. In detail, expression levels of EBF1, MYO6, CALR are associated with a significant worse overall survival.ConclusionsThese results pave the way for a novel characterization of DLBCL biomarkers, aiding the stratification of responder versus non-responder patients. |
| first_indexed | 2024-03-11T10:38:51Z |
| format | Article |
| id | doaj.art-b198c3f32aad41e698a82358a2a2963c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-11T10:38:51Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b198c3f32aad41e698a82358a2a2963c2023-11-14T09:43:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-11-011410.3389/fimmu.2023.12662651266265EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomasAlice Turdo0Miriam Gaggianesi1Caterina D’Accardo2Gaetana Porcelli3Sebastiano Di Bella4Dario Cricchio5Irene Pillitteri6Rossana Porcasi7Melania Lo Iacono8Francesco Verona9Chiara Modica10Narges Roozafzay11Ada Maria Florena12Giorgio Stassi13Salvatrice Mancuso14Matilde Todaro15Matilde Todaro16Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Surgical, Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, ItalyA.O.U.P. “Paolo Giaccone”, University of Palermo, Palermo, ItalyBackgroundDiffuse large B-cell lymphoma (DLBCL) is a hematological malignancy representing one-third of non-Hodgkin’s lymphoma cases. Notwithstanding immunotherapy in combination with chemotherapy (R-CHOP) is an effective therapeutic approach for DLBCL, a subset of patients encounters treatment resistance, leading to low survival rates. Thus, there is an urgent need to identify predictive biomarkers for DLBCL including the elderly population, which represents the fastest-growing segment of the population in Western countries.MethodsGene expression profiles of n=414 DLBCL biopsies were retrieved from the public dataset GSE10846. Differentially expressed genes (DEGs) (fold change >1.4, p-value <0.05, n=387) have been clustered in responder and non-responder patient cohorts. An enrichment analysis has been performed on the top 30 up-regulated genes of responder and non-responder patients to identify the signatures involved in gene ontology (MSigDB). The more significantly up-regulated DEGs have been validated in our independent collection of formalin-fixed paraffin-embedded (FFPE) biopsy samples of elderly DLBCL patients, treated with R-CHOP as first-line therapy.ResultsFrom the analysis of two independent cohorts of DLBCL patients emerged a gene signature able to predict the response to R-CHOP therapy. In detail, expression levels of EBF1, MYO6, CALR are associated with a significant worse overall survival.ConclusionsThese results pave the way for a novel characterization of DLBCL biomarkers, aiding the stratification of responder versus non-responder patients.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1266265/fulldiffuse large B-cell lymphomaR-CHOPtherapy resistanceelderly patientsgene expression signaturebiomarkers of response |
| spellingShingle | Alice Turdo Miriam Gaggianesi Caterina D’Accardo Gaetana Porcelli Sebastiano Di Bella Dario Cricchio Irene Pillitteri Rossana Porcasi Melania Lo Iacono Francesco Verona Chiara Modica Narges Roozafzay Ada Maria Florena Giorgio Stassi Salvatrice Mancuso Matilde Todaro Matilde Todaro EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas Frontiers in Immunology diffuse large B-cell lymphoma R-CHOP therapy resistance elderly patients gene expression signature biomarkers of response |
| title | EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas |
| title_full | EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas |
| title_fullStr | EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas |
| title_full_unstemmed | EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas |
| title_short | EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas |
| title_sort | ebf1 myo6 and calr expression levels predict therapeutic response in diffuse large b cell lymphomas |
| topic | diffuse large B-cell lymphoma R-CHOP therapy resistance elderly patients gene expression signature biomarkers of response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1266265/full |
| work_keys_str_mv | AT aliceturdo ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT miriamgaggianesi ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT caterinadaccardo ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT gaetanaporcelli ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT sebastianodibella ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT dariocricchio ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT irenepillitteri ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT rossanaporcasi ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT melanialoiacono ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT francescoverona ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT chiaramodica ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT nargesroozafzay ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT adamariaflorena ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT giorgiostassi ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT salvatricemancuso ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT matildetodaro ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas AT matildetodaro ebf1myo6andcalrexpressionlevelspredicttherapeuticresponseindiffuselargebcelllymphomas |